All studies
Active not recruitingNAINTERVENTIONAL

Nasal Immune Challenge Study

Chest infections caused by common viruses can make life difficult, especially for people with asthma or nasal allergies. In this study, UK researchers want to understand how the body's natural defences fight off these bugs. Instead of giving people a real virus, researchers will use a nasal spray containing a substance called Resiquimod (or R848). This harmless substance acts like a virus to trick the lining of the nose into thinking it has a mild cold. Because it contains no living germs, you cannot catch a real illness from it. Scientists will compare nasal and blood samples from healthy volunteers with those from people who have asthma or allergies. This will help them learn why some people react more severely to viruses, paving the way for improved, targeted treatments in the future.

At a glance

Status
Active not recruiting
Phase
NA
Sponsor
Cambridge University Hospitals NHS Foundation Trust
Enrolment target
24
Start
09 Aug 2022
Estimated completion
30 Sep 2027

What is this study about?

When you catch a cold, the virus usually enters through your nose before heading toward your airways. For many people, a cold is just an annoyance. However, for those living with lung conditions like asthma, catching a virus can trigger severe chest tightness, wheezing, and hospital visits. Current treatments often rely on strong steroid medications, which have not changed much in decades. Scientists are eager to find newer, gentler ways to protect vulnerable airways.

To study respiratory infections safely, researchers do not need to give people a live, dangerous virus. The inside of your nose has cells very similar to those found deeper in your lungs. In this study, scientists use a special nasal spray called Resiquimod (R848) alongside a simple saltwater (saline) spray. Resiquimod mimics the way a virus alerts your immune system, causing temporary, mild symptoms like a stuffy or runny nose, but without causing a real infection.

By taking small samples from the nose and checking blood tests, the research team can see how the body's first line of defence springs into action. They want to compare the natural defences of healthy volunteers against those of people with hay fever, pet allergies, or mild asthma. Understanding these subtle differences could help doctors design better vaccines and treatments to stop viral flare-ups before they start.

Key takeaways

  • Researchers are using a harmless nasal spray to safely mimic a mild cold virus.
  • The study aims to understand how our natural defences react in people with and without asthma.
  • The nasal spray cannot cause a real infection because it contains no living germs.
  • The trial involves adults aged 18 and older, including healthy individuals and those with allergies or mild asthma.
  • Taking part is voluntary, and you can withdraw at any time without your normal NHS care being affected.

Who may be eligible?

This study is open to adults aged 18 and over who fall into one of two main groups: healthy volunteers, or people with allergic rhinitis (such as hay fever or dust allergies) with or without mild-to-moderate asthma. All participants must have a negative COVID-19 test before taking part, normal heart trace (ECG) results, and be willing to let the researchers contact their GP.

Healthy volunteers must have no past history of asthma, eczema, or allergies, and must show normal results on lung breathing tests and allergy skin checks. Volunteers with allergies should have a clear history of allergy symptoms (like sneezing and an itchy nose) confirmed by a skin test, and their asthma—if they have it—must be well controlled on standard daily inhalers.

People cannot take part if they are pregnant or breastfeeding, or if they are not using reliable contraception. You will also be excluded if your asthma is poorly controlled, if your lung function is too low, or if you have recently taken steroid tablets, steroid nasal sprays, or other non-standard medications in the four weeks before starting.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I am either in good health with no allergies, or I have diagnosed allergies (with or without mild asthma).
  3. If I have asthma, it is well controlled using standard inhalers.
  4. I have not taken steroid tablets or steroid nasal sprays in the past 4 weeks.
  5. I am not pregnant or breastfeeding, and I am willing to use reliable contraception.
  6. I am happy for my GP to be notified about my participation.
Answer every question to see your result.

What does participation involve?

If you take part, you will first attend a screening visit to check your general health, including an ECG (heart trace), routine blood tests, a COVID-19 test, and a simple breathing test to measure your lung strength. You will receive either the study nasal spray (Resiquimod) or a simple saltwater spray (saline) into your nostrils. Researchers will monitor you closely and collect routine samples, such as gentle nasal swabs, nasal fluid washings, and small blood samples over a set period. Your doctor or the study team will let you know the exact schedule of clinic visits and how long the study will last before you decide to join.

Potential risks and benefits

You will not receive any direct medical benefit from joining this study, but your participation could help scientists discover better treatments for people with asthma and respiratory conditions in the future. The nasal spray does not contain living germs, but it may cause short-lived symptoms similar to a mild head cold, such as a runny or blocked nose and sneezing. Taking nasal swabs or blood samples may also cause brief discomfort or mild bruising. Your safety is closely monitored throughout, and you are free to leave the study at any time without giving a reason and without it affecting your regular medical care.

Locations (1)

  • Cambridge University Hospitals NHS Foundation Trust
    Verified postcode
    Cambridge, United Kingdom

Common questions

Can I catch a real viral infection from the study spray?

No. The spray contains Resiquimod, which is a man-made substance that acts like a virus to trigger your defences. It has no living organisms, so it cannot multiply or cause an actual infection.

What will the spray feel like?

Most people experience mild symptoms similar to the start of a head cold, such as a tickly or runny nose, mild congestion, or sneezing. These effects are temporary and settle on their own.

Do I need to stop using my regular asthma inhalers?

Volunteers with asthma are usually allowed to continue standard preventer and reliever inhalers, but you should discuss all current medications with the research team first.

Will taking part cost me anything?

No, taking part is free. Many clinical trials also help cover reasonable travel expenses. You can ask the study team for details about travel support.

Can I leave the study if I change my mind?

Yes. Taking part is completely voluntary. You are free to stop and withdraw at any point, and your normal healthcare will never be affected.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.